Citizens JMP lowered the firm’s price target on KalVista (KALV) to $28 from $29 and keeps an Outperform rating on the shares. Early demand for Ekterly looks strong, with 937 start forms as of the end of October, covering roughly 8% of the diagnosed U.S. hereditary angioedema population, the analyst tells investors in a research note. The 937 start forms represent about $31M in potential revenue, the firm notes, adding that the early demand is “promising.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista Pharmaceuticals: Strong Market Performance and Growth Potential Justify Buy Rating
- KalVista reports Q3 EPS (92c) vs. (84c) last year
- Buy Rating for KalVista Pharmaceuticals Driven by Strong Ekterly Uptake and Optimistic Revenue Projections
- KalVista’s Pediatric HAE Study: A Potential Game-Changer?
- KalVista’s Icatibant Study: A Potential Game-Changer for HAE Treatment?